Conceptos Básicos
Weight loss is the key treatment for NAFLD and NASH, with various methods available for negotiation with patients to achieve significant benefits in reducing the risks associated with these conditions.
Resumen
The content discusses the importance of weight loss as a treatment for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). It emphasizes the significance of negotiating with patients on various methods to achieve weight loss and reduce the risks associated with diabetes, obesity, and liver complications. The article highlights the role of primary care clinicians in identifying patients at risk, utilizing tools like the FIB-4 assessment, and referring high-risk individuals to hepatologists for further management. Communication with patients and lifestyle modifications are crucial aspects of managing NAFLD and NASH effectively.
Highlights:
- Weight loss is the primary treatment for NAFLD and NASH.
- Negotiation with patients on methods for weight loss is essential.
- Strategies include lifestyle changes, exercise, medication, and bariatric surgery.
- FIB-4 assessment helps identify patients at risk for advanced fibrosis.
- Referral to hepatologists is recommended for high-risk individuals.
- Communication and lifestyle modifications play a vital role in patient management.
Estadísticas
"losing at least 5% of body weight would be beneficial for reducing the effects of diabetes and obesity."
"A 10% reduction reduces the chance of progression from NAFLD to NASH or from NASH to early fibrosis."
"Perhaps as many as 35% of Americans and 30% of people worldwide have NAFLD."
Citas
"Weight loss is the treatment; you negotiate with your patients the method." - Jay Shubrook, DO
"Most people with NAFLD and NASH still die of cardiovascular disease." - Jay Shubrook, DO
"Our goal is to identify people most at risk of progression to cirrhosis, and then to prevent it." - Nancy S. Reau, MD